FcRL4+ B-cells in salivary glands of primary Sjögren's syndrome patients

Journal of Autoimmunity

Volumn 81, Issue , 2017, Pages 90-98

  Haacke, Erlin A ^a   Bootsma, Hendrika ^a   Spijkervet, Fred K L ^a   Visser, Annie ^a   Vissink, Arjan ^a   Kluin, Philip M ^a   Kroese, Frans G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Abatacept; FcRL4; MALT lymphoma; Rituximab; Salivary gland; Sj gren's syndrome

Indexed keywords

ABATACEPT; AUTOANTIBODY; CD20 ANTIGEN; FC RECEPTOR; FC RECEPTOR LIKE PROTEIN 4; KI 67 ANTIGEN; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; FCRL4 PROTEIN, HUMAN;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABIAL GLAND TISSUE; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; PAROTID GLAND; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SALIVARY GLAND; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; AGED; BIOPSY; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PRECANCER; SALIVA;

ADULT; AGED; ANTIGENS, CD20; B-LYMPHOCYTES; BIOPSY; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PHENOTYPE; PRECANCEROUS CONDITIONS; RECEPTORS, FC; RITUXIMAB; SALIVA; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 85017147609     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2017.03.012     Document Type: Article

References (36)

1. Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S.J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., Ramos-Casals, M., Sjögren syndrome. Nat. Rev. Dis. Prim. 2 (2016), 1–20.
2. Christodoulou, M.I., Kapsogeorgou, E.K., Moutsopoulos, H.M., Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J. Autoimmun. 34 (2010), 400–407.
3. Ihrler, S., Zietz, C., Sendelhofert, A., Riederer, A., Löhrs, U., Lymphoepithelial duct lesions in Sjögren-type sialadenitis. Virchows Arch. 434 (1999), 315–323.
4. Pijpe, J., Kalk, W.W.I., van der Wal, J.E., Vissink, A., Kluin, P.M., Roodenburg, J.L.N., Bootsma, H., Kallenberg, C.G.M., Spijkervet, F.K.L., Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatol. Oxf. 46 (2007), 335–341.
5. Kroese, F.G.M., Abdulahad, W.H., Haacke, E., Bos, N.A., Vissink, A., Bootsma, H., B-cell hyperactivity in primary Sjögren's syndrome. Expert Rev. Clin. Immunol. 10 (2014), 483–499.
6. Giannouli, S., Voulgarelis, M., Predicting progression to lymphoma in Sjögren's syndrome patients. Expert Rev. Clin. Immunol. 10 (2014), 501–512.
7. Voulgarelis, M., Ziakas, P.D., Papageorgiou, A., Baimpa, E., Tzioufas, A.G., Moutsopoulos, H.M., Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Med. Baltim. 91 (2012), 1–9.
8. Nocturne, G., Boudaoud, S., Miceli-Richard, C., Viengchareun, S., Lazure, T., Nititham, J., Taylor, K.E., Ma, A., Busato, F., Melki, J., Lessard, C.J., Sivils, K.L., Dubost, J.-J., Hachulla, E., Gottenberg, J.E., Lombès, M., Tost, J., Criswell, L.A., Mariette, X., Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 122 (2013), 4068–4076.
9. Isaacson, P.G., Norton, A.J., Extranodal Lymphomas. 1994, Churchill Livingstone.
10. Bacon, C.M., Du, M.-Q., Dogan, A., Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. J. Clin. Pathol. 60 (2007), 361–372.
11. Falini, B., Agostinelli, C., Bigerna, B., Pucciarini, A., Pacini, R., Tabarrini, A., Falcinelli, F., Piccioli, M., Paulli, M., Gambacorta, M., Ponzoni, M., Tiacci, E., Ascani, S., Martelli, M.P., Dalla Favera, R., Stein, H., Pileri, S. a, IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology 61 (2012), 930–941.
12. Masaki, Y., Sugai, S., Lymphoproliferative disorders in Sjögren's syndrome. Autoimmun. Rev. 3 (2004), 175–182.
13. Falini, B., Tiacci, E., Pucciarini, A., Bigerna, B., Kurth, J., Hatzivassiliou, G., Droetto, S., Galletti, B.V., Gambacorta, M., Orazi, A., Pasqualucci, L., Miller, I., Kuppers, R., Dalla-Favera, R., Cattoretti, G., Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood 102 (2003), 3684–3692.
14. Ehrhardt, G.R., Hsu, J.T., Gartland, L., Leu, C.-M., Zhang, S., Davis, R.S., Cooper, M.D., Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J. Exp. Med. 202 (2005), 783–791.
15. Wilson, T.J., Fuchs, A., Colonna, M., Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J. Immunol. 188 (2012), 4741–4745.
16. Sohn, H.W., Krueger, P.D., Davis, R.S., Pierce, S.K., FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. Blood 118 (2011), 6332–6341.
17. Yeo, L., Lom, H., Juarez, M., Snow, M., Buckley, C.D., Filer, A., Raza, K., Scheel-Toellner, D., Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann. Rheum. Dis. 74 (2015), 928–935.
18. Meijer, J.M., Meiners, P.M., Vissink, A., Spijkervet, F.K.L., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C.G.M., Bootsma, H., Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62 (2010), 960–968.
19. Delli, K., Haacke, E.A., Kroese, F.G.M., Pollard, R.P., Ihrler, S., van der Vegt, B., Vissink, A., Bootsma, H., Spijkervet, F.K.L., Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann. Rheum. Dis. 75 (2016), 1933–1938.
20. Meiners, P.M., Vissink, A., Kroese, F.G.M., Spijkervet, F.K.L., Smitt-Kamminga, N.S., Abdulahad, W.H., Bulthuis-Kuiper, J., Brouwer, E., Arends, S., Bootsma, H., Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann. Rheum. Dis. 73 (2014), 1393–1396.
21. Haacke, E.A., van der Vegt, B., Meiners, P.M., Vissink, A., Spijkervet, F.K.L., Bootsma, H., Kroese, F.G.M., Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue. Clin. Exp. Rheumatol. 35 (2017), 317–320.
22. Greenspan, J.S., Daniels, T.E., Talal, N., Sylvester, R.A., The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg. Oral Med. Oral Pathol. 37 (1974), 217–229.
23. Cuello, C., Palladinetti, P., Tedla, N., Di Girolamo, N., Lloyd, A.R., McCluskey, P.J., Wakefield, D., Chemokine expression and leucocyte infiltration in Sjögren's syndrome. Br. J. Rheumatol. 37 (1998), 779–783.
24. Ehrhardt, G.R., Hijikata, A., Kitamura, H., Ohara, O., Wang, J.-Y., Cooper, M.D., Discriminating gene expression profiles of memory B cell subpopulations. J. Exp. Med. 205 (2008), 1807–1817.
25. Guerrier, T., Le Pottier, L., Devauchelle, V., Pers, J.-O., Jamin, C., Youinou, P., Role of Toll-like receptors in primary Sjögren's syndrome with a special emphasis on B-cell maturation within exocrine tissues. J. Autoimmun. 39 (2012), 69–76.
26. Zheng, L., Zhang, Z., Yu, C., Yang, C., Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 109 (2010), 844–850.
27. Polihronis, M., Tapinos, N.I., Theocharis, S.E., Economou, A., Kittas, C., Moutsopoulos, H.M., Modes of epithelial cell death and repair in Sjögren's syndrome (SS). Clin. Exp. Immunol. 114 (1998), 485–490.
28. Manoussakis, M.N., Kapsogeorgou, E.K., The role of intrinsic epithelial activation in the pathogenesis of Sjögren's syndrome. J. Autoimmun. 35 (2010), 219–224.
29. Lund, F.E., Cytokine-producing B lymphocytes-key regulators of immunity. Curr. Opin. Immunol. 20 (2008), 332–338.
30. Koch, S., Nusrat, A., The life and death of epithelia during inflammation: lessons learned from the gut. Annu. Rev. Pathol. 7 (2012), 35–60.
31. Pijpe, J., Meijer, J.M., Bootsma, H., van der Wal, J.E., Spijkervet, F.K.L., Kallenberg, C.G.M., Vissink, A., Ihrler, S., Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum. 60 (2009), 3251–3256.
32. Keszler, A., Adler, L.I., Gandolfo, M.S., Masquijo Bisio, P. a, Smith, a C., Vollenweider, C.F., Heidenreich, a M., de Stefano, G., Kambo, M.V., Cox, D.P., Narbaitz, M., Lanfranchi, H.E., MALT lymphoma in labial salivary gland biopsy from Sjögren syndrome: importance of follow-up in early detection. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 115 (2013), e28–33.
33. Matsumoto, Y., Marusawa, H., Kinoshita, K., Endo, Y., Kou, T., Morisawa, T., Azuma, T., Okazaki, I.-M., Honjo, T., Chiba, T., Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 13 (2007), 470–476.
34. R. Kumar, L.J. DiMenna, J. Chaudhuri, T. Evans, Biological function of activation-induced cytidine deaminase (AID)., Biomed. J. 37 269–283.
35. Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., Rosenberg, S.A., Coltman, C.A., Tubiana, M., Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J. Clin. Oncol. 7 (1989), 1630–1636.
36. Musshoff, K., Clinical staging classification of non-Hodgkin's lymphomas (author's transl). Strahlentherapie 153 (1977), 218–221.